A Study of DM001 in Patients With Advanced Solid Tumors

This is a Phase 1, multicenter, openlabel, first-in-human (FIH), doseescalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of DM001 in subjects with advanced solid tumors. DM001, a bispecific ADC developed using fully human antibodies with a common light chain, which targets TROP2 and EGFR. DM001 is sterile yellowish-green lyophilized powder for IV infusion. Subjects with solid malignant tumors will be treated with DM001 on Day 1 once Q3W (dose adjustments may be required depending on the safety profile and PK data of each dose).